Fig. 3

In vivo toxicity of CDNVs. A Representative images of H&E-stained liver, kidney, heart, lung and spleen sections from the indicated groups (n = six mice per group). Scale bar represents 200 μm. B-D The levels of liver injury-related biomarkers (serum ALT and AST) and kidney injury-related biomarkers (serum creatinine (CR)) in the indicated groups (n = six mice per group). Data represent means ± SD. ns, not significant. The details for each group were shown as below: PBS ig.: mice were orally administered with 200 µL of PBS; CDNVs ig.: mice were orally administered with 40 mg/kg of CDNVs; HSYA ig.: mice were orally administered with 0.27 mg/kg HSYA; PBS iv.: mice were intravenously administered with 200 µL of PBS; CDNVs iv.: mice were intravenously administered with 40 mg/kg of CDNVs; HSYA iv.: mice were intravenously administered with 0.27 mg/kg HSYA. All treatments were administered three times per week for 12 weeks. The H&E staining and the measurement of serum biomarkers were performed at the end of the 12-week treatment period